Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Abraxane, and Sorafenib in Metastatic Melanoma
NCT00483301Phase 2Completed
- Sponsor
- Mount Sinai Medical Center
- Start
- May 2007
- Primary completion
- Aug 2009
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and nab-paclitaxel in Malignant Melanoma (MM), sponsored by Mount Sinai Medical Center. Primary endpoint: Response Rate. Started May 2007; status: completed.
02
Drugs
sorafenibnab-paclitaxel
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00483301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483301.